Dimensional Fund Advisors LP Kiniksa Pharmaceuticals, Ltd. Transaction History

Dimensional Fund Advisors LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.63 - $21.74 $2.76 Million - $3.4 Million	156,546 Added 44.76%	506,299 $9.99 Million
Q4 2023 Feb 07, 2024	SELL	$14.37 - $19.07 $344,420 - $457,069	-23,968 Reduced 6.41%	349,753 $6.13 Million
Q3 2023 Nov 09, 2023	SELL	$13.62 - $20.2 $18,904 - $28,037	-1,388 Reduced 0.37%	373,721 $6.49 Million
Q2 2023 Aug 09, 2023	SELL	$10.44 - $16.48 $22,435 - $35,415	-2,149 Reduced 0.57%	375,109 $5.28 Million
Q1 2023 May 12, 2023	SELL	$10.7 - $15.79 $166,203 - $245,266	-15,533 Reduced 3.95%	377,258 $4.06 Million
Q4 2022 Feb 09, 2023	SELL	$11.42 - $17.05 $7,708 - $11,508	-675 Reduced 0.17%	392,791 $5.88 Million
Q3 2022 Nov 10, 2022	SELL	$9.76 - $13.41 $133,526 - $183,462	-13,681 Reduced 3.36%	393,466 $5.05 Million
Q2 2022 Aug 12, 2022	BUY	$7.6 - $11.41 $351,173 - $527,221	46,207 Added 12.8%	407,147 $3.95 Million
Q1 2022 May 13, 2022	BUY	$9.3 - $12.37 $1.88 Million - $2.49 Million	201,622 Added 126.55%	360,940 $3.59 Million
Q4 2021 Feb 09, 2022	BUY	$10.39 - $15.15 $260,072 - $379,219	25,031 Added 18.64%	159,318 $1.88 Million
Q3 2021 Nov 12, 2021	SELL	$11.39 - $16.23 $2.21 Million - $3.15 Million	-193,927 Reduced 59.09%	134,287 $1.53 Million
Q2 2021 Aug 12, 2021	BUY	$13.22 - $19.09 $1.19 Million - $1.72 Million	90,167 Added 37.88%	328,214 $4.57 Million
Q1 2021 May 14, 2021	BUY	$16.68 - $23.97 $2.72 Million - $3.91 Million	163,191 Added 218.01%	238,047 $4.41 Million
Q4 2020 Feb 25, 2021	BUY	$14.8 - $21.15 $1.11 Million - $1.58 Million	74,856 New	74,856 $1.32 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.